PegiHep contains Pegylated Interferon alfa-2a or alfa-2b, an immunomodulatory and antiviral agent used primarily for the treatment of chronic Hepatitis B (HBV) and Hepatitis C (HCV) infections. The pegylation prolongs the drug’s half-life, allowing once-weekly subcutaneous injections for sustained antiviral activity.

Mechanism of Action

• Pegylated interferon binds to interferon receptors on host cells.

• Activates JAK-STAT signaling pathways, inducing expression of interferon-stimulated genes (ISGs).

• These ISGs inhibit viral replication and enhance the immune system’s ability to target infected cells.

• Pegylation increases circulatory half-life, providing prolonged antiviral and immunomodulatory effects.

  Uses

  • Treatment of chronic Hepatitis B virus (HBV) infection.

  • Treatment of chronic Hepatitis C virus (HCV) infection, often in combination with antiviral agents.

  • Sometimes used in other viral infections or certain cancers (off-label).

  • Helps reduce viral load, liver inflammation, and progression to cirrhosis or hepatocellular carcinoma.

    Adverse Effects

    • Flu-like symptoms (fever, fatigue, headache, muscle aches)

    • Injection site reactions

    • Nausea, vomiting, or diarrhea

    • Mild depression or irritability